Mobic, Zynrelef(meloxicam)
Meloxicam, Zynrelef (meloxicam) is a small molecule pharmaceutical. Meloxicam was first approved as Mobic on 2000-04-13. It is used to treat osteoarthritis and rheumatoid arthritis in the USA. It has been approved in Europe to treat postoperative pain. The pharmaceutical is active against prostaglandin G/H synthase 2. In addition, it is known to target prostaglandin G/H synthase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Meloxicam (discontinued: Anjeso, Meloxicam, Mobic, Qmiiz, Vivlodex)
CombinationsZynrelef (discontinued: Zynrelef)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Meloxicam
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MELOXICAM | Avondale Pharmaceuticals | N-021530 RX | 2004-06-01 | 1 products, RLD, RS |
Show 4 discontinued
Bupivacaine
+
Meloxicam
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZYNRELEF KIT | Heron Therapeutics | N-211988 RX | 2021-05-12 | 2 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| meloxicam | ANDA | 2025-01-07 |
| mobic | ANDA | 2021-03-30 |
| trepoxicam | unapproved drug other | 2010-10-25 |
| trepoxicam-7.5 | unapproved drug other | 2011-08-01 |
| vivlodex | New Drug Application | 2021-04-30 |
| zynrelef | New Drug Application | 2024-12-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| rheumatoid arthritis | EFO_0000685 | D001172 | M06.9 |
| osteoarthritis | EFO_0002506 | D010003 | M15-M19 |
| postoperative pain | — | D010149 | G89.18 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
BUPIVACAINE / MELOXICAM, ZYNRELEF KIT, HERON THERAPS INC | |||
| 2024-05-12 | NP | ||
MELOXICAM, ANJESO, BAUDAX | |||
| 2023-02-20 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Meloxicam, Anjeso, Baudax | |||
| 10881663 | 2039-03-08 | U-3038 | |
| 11458145 | 2039-03-08 | U-3318 | |
| 9974746 | 2030-05-26 | DP | |
| 10709713 | 2030-05-26 | U-2750 | |
| 11253478 | 2030-05-26 | DP | U-3318 |
| 10463673 | 2024-02-24 | DP | U-2750 |
| 10471067 | 2024-02-24 | DP | U-2750 |
| Bupivacaine / Meloxicam, Zynrelef Kit, Heron Theraps Inc | |||
| 9694079 | 2035-04-20 | DP | U-3118 |
| 9801945 | 2035-04-20 | DP | U-3118 |
| 10098957 | 2035-04-20 | U-3118 | |
| 10213510 | 2035-04-20 | DP | U-3118 |
| 10632199 | 2035-04-20 | DP | U-3118 |
| 10898575 | 2035-04-20 | DP | U-3118 |
| 10980886 | 2035-04-20 | DP | |
| 11083730 | 2035-04-20 | DP | U-3118 |
| 11083797 | 2035-04-20 | DP | U-3118 |
| 11413350 | 2035-04-20 | U-3417 | |
| 9592227 | 2034-03-13 | DP | U-3118 |
| 9744163 | 2034-03-13 | DP | |
| 9913909 | 2034-03-13 | U-3118 | |
| 10398686 | 2034-03-13 | DP | |
| 11253504 | 2034-03-13 | U-3118 | |
| Meloxicam, Vivlodex, Iceutica Operations | |||
| 9649318 | 2035-03-31 | DP | |
| 9808468 | 2035-03-31 | U-2160, U-2165 | |
| 9526734 | 2033-03-31 | DP | |
| Meloxicam, Qmiiz Odt, Tersera | |||
| 8545879 | 2030-08-31 | DP | |
ATC Codes
M: Musculo-skeletal system drugs
— M01: Antiinflammatory and antirheumatic products
— M01A: Antiinflammatory and antirheumatic products, non-steroids
— M01AC: Oxicams, antiinflammatory and antirheumatic drugs
— M01AC06: Meloxicam
— M01AC56: Meloxicam, combinations
N: Nervous system drugs
— N01: Anesthetics
— N01B: Local anesthetics
— N01BB: Amide local anesthetics
— N01BB59: Bupivacaine and meloxicam
Clinical
No data
Drug
General
| Drug common name | Meloxicam |
| INN | meloxicam |
| Description | Meloxicam is a benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis. It has a role as a non-steroidal anti-inflammatory drug, an antirheumatic drug, a cyclooxygenase 2 inhibitor and an analgesic. It is a benzothiazine, a monocarboxylic acid amide and a member of 1,3-thiazoles. |
| Classification | Small molecule |
| Drug class | anti-inflammatory agents (isoxicam type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1 |
Identifiers
| PDB | — |
| CAS-ID | 71125-38-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL599 |
| ChEBI ID | 6741 |
| PubChem CID | 54677470 |
| DrugBank | DB00814 |
| UNII ID | VG2QF83CGL (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Zynrelef – Heron Therapeutics /de/
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Meloxicam
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
Black-box warning for: Meloxicam, Trepoxicam, Trepoxicam-7.5, Vivlodex, Zynrelef
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use